BUSINESS WIRE: Gilead Sciences' Chief Scientific Officer John McHutchison to Leave the Company

17.07.2019, 14:30 Uhr


FOSTER CITY, Calif. --(BUSINESS WIRE)-- 17.07.2019 --

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that John McHutchison, AO, MD, Chief Scientific Officer and Head of Research & Development, has decided to leave the company, effective next month. The company will immediately commence a search for his successor.

Dr. McHutchison joined Gilead in 2010 and under his leadership, Gilead has developed five medicines that have been used by more than 3.2 million people around the world for the curative treatment of chronic hepatitis C, and treatment of chronic hepatitis B. He also oversaw the company's expansion into oncology with the development of Gilead's first cancer medicine, Zydelig® (idelalisib). He was appointed Chief Scientific Officer in March 2018. During his tenure, he has been responsible for broadening and overseeing the company's Research and Development pipeline, advancing candidates in new therapeutic areas, including oncology, cell therapy and inflammation.

"Over the past nine years, John's scientific contributions and leadership have played an instrumental role in shaping our research efforts and in improving care for millions of patients with life-threatening illnesses," said Daniel O'Day, Chairman and Chief Executive Officer of Gilead. "Under his guidance, the company was able to rapidly advance our hepatitis C portfolio, enabling therapies to reach people in need at an unprecedented pace, and he has continued to build on that work by helping the company expand its therapeutic areas of focus. We are grateful to John for his many contributions and wish him the best."

"It has been a privilege to work alongside many exceptionally talented scientists," said Dr. McHutchison. "I am grateful for the opportunity to make a difference in the lives of people with serious illnesses and confident that Gilead will continue to advance important new medicines for generations of patients to come."


About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information about Gilead, please visit the company's website at, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Sung Lee, Investors
(650) 524-7792

Amy Flood, Media
(650) 522-5643

Weitere Nachrichten

25.01. BUSINESS WIRE: HCL Technologies ehrt globale Goodwill Champions beim Weltwirtschaftsforum 2020 in Davos
25.01. GlobeNewswire: Posterpräsentation von ERYTECH für TRYbeCA1 auf der ASCO 2020
24.01. BUSINESS WIRE: Sierra Metals meldet überragende Produktionsergebnisse für 2019 und veröffentlicht Prognose für 2020
24.01. BUSINESS WIRE: HighRes Biosolutions und Novo Nordisk arbeiten gemeinsam an Transformation der Arzneimittelentwicklung im automatisierten Labor der Zukunft
24.01. BUSINESS WIRE: Conquest investiert in 5 Greenfield-Onshore-Windparks mit einer Gesamtleistung von 43 MW in der Region Flandern
24.01. BUSINESS WIRE: Deutsche Gewächshausregion Emsland entscheidet sich für Fluence by Osram
24.01. BUSINESS WIRE: Ipsen’s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteria
24.01. GlobeNewswire: Compagnie Financière Tradition: Adjusted revenue of CHF 1,012.5m in 2019, growth of 4.7% in constant currencies
24.01. BUSINESS WIRE: Amazentis meldet Einführung von Timeline™ Zellnahrung auf dem Weltwirtschaftsforum in Davos
24.01. GlobeNewswire: Avis Budget Group und Fiat Chrysler Automobiles unterzeichnen neuen Vertrag über vernetzte Fahrzeuge, um in Europa effizientere Self-Service- und On-Demand-Mietwagenlösungen anzubieten